Loading...
•
Dec 31, 2025
Multiplan Q4 2025 Earnings Report
Claritev reported increased fourth quarter 2025 revenues with a reduced net loss and strong Adjusted EBITDA performance.
Key Takeaways
Claritev generated fourth quarter 2025 revenues of 246554000, up year-over-year, with a net loss of 80570000 and Adjusted EBITDA of 151326000. The company delivered positive free cash flow and significant medical cost savings from processed claims.
Q4 2025 revenues increased 6.2% year-over-year to 246554000.
Net loss narrowed to 80570000 from 137965000 in Q4 2024.
Adjusted EBITDA rose to 151326000 with a 61.4% margin.
Free cash flow improved to 36377000, supported by 66286000 in operating cash flow.
Forward Guidance
For full-year 2026, Claritev expects revenues between 980000000 and 1000000000, Adjusted EBITDA between 605000000 and 615000000, capital expenditures between 160000000 and 170000000, and free cash flow between 0 and 10000000.
Positive Outlook
- Revenue guidance of 980000000 to 1000000000 for FY 2026.
- Adjusted EBITDA guidance of 605000000 to 615000000.
- Expected return to positive free cash flow in 2026.
- Free cash flow guidance of 0 to 10000000.
- Board approved 75000000 share repurchase program.
Challenges Ahead
- Capital expenditures expected between 160000000 and 170000000.
- Guidance excludes GAAP reconciliation for Adjusted EBITDA.
- Ongoing transformation and refinancing related costs may impact results.
- High interest expense burden remains.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...